profit from every $100 of sales.
$0$100
Ascendis Pharma
$275.39+3.12% today
+33.4% in 1 year
1-year low $196.631-year high $277.18
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Ascendis Pharma sold, what it kept, and what it did with the cash.
Sales went from €51.2 million in 2022 to €720 million in 2025, with -€228 million of profit last year.
SalesProfit
Ascendis Pharma handed back 38% of the cash it generated last year.
Buybacks €17M
Free cash flow 2025€45M
Bought back its own shares€17M
Paid as dividends–
Cash vs. debt€616M vs. €872M
Ascendis Pharma vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Ascendis Pharma | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Ascendis Pharma's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 51 | 267 | 364 | 720 | |
| 39 | 222 | 319 | 625 | |
| -562 | -456 | -279 | -136 | |
| -529 | -411 | -290 | -114 | |
| -583 | -481 | -378 | -228 | |
| -10.40 | -8.55 | -6.53 | -3.76 | |
| 76.3% | 83.4% | 87.8% | 86.8% | |
| -1,097.9% | -170.8% | -76.7% | -18.9% | |
| -1,139.6% | -180.5% | -104.0% | -31.7% |
Balance sheet
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 1,090 | 826 | 1,179 | 1,303 |
| Cash | 445 | 392 | 560 | 616 |
| Total debt | 508 | 644 | 857 | 872 |
| Total liabilities | 826 | 971 | 1,285 | 1,465 |
| 263 | -146 | -106 | -163 | |
| 56 | 56 | 58 | 61 | |
| -56.0% | -68.1% | -32.4% | -14.7% | |
| -221.5% | 330.4% | 357.7% | 140.1% |
Cash flow
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -496 | -467 | -306 | 54 | |
| 14 | 2 | 1 | 8 | |
| -510 | -470 | -308 | 45 | |
| Dividends paid | – | – | – | – |
| 105 | 0 | 0 | 17 | |
| 64 | 67 | 96 | 116 |
Valuation
- –
- 69.1×
- –
- 26.0×
- 22.7×
- 360.7×
- –
- 0.3%
- -1.4%
- 0.0%
Profitability
- 86.8%
- -18.9%
- -31.7%
- -0.8%
- 1.5%
- -52.6%
- -5,641.9%
- 25.3%
- -0.8%
- 31.3%
Growth
- +141.4%
- –
- +114.2%
- –
- +2.6%
Financial health
- –
- 1.84
- 44.8%
- -0.0×
- 1.00
- 0.72
- 0.43
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 40%of 946
Bottom 12%of 871
Top 4%of 867
Bottom 42%of 986
What analysts expect
- Average price target
- $287.17
- Range
- $250.00 – $342.00
- 10 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 7, 2026 | 0.32 | 0.21 | +52.4% |
| Feb 11, 2026 | -0.64 | -0.06 | −966.7% |
| Nov 12, 2025 | -1.17 | -0.41 | −185.4% |
| Aug 7, 2025 | -0.93 | -1.42 | +34.5% |
| May 1, 2025 | -1.66 | -1.56 | −6.4% |
| Feb 12, 2025 | -0.68 | -1.20 | +43.3% |
| Nov 14, 2024 | -1.81 | -1.83 | +1.1% |
| Sep 3, 2024 | -2.05 | -1.54 | −33.1% |
News
Ascendis Pharma sets $400M stock buyback planSeeking Alpha · Sep 15, 2026The newest story we have is from Sep 15, 2026.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
13No pass
Benjamin Graham
14No pass
Philip Fisher
40No pass
Peter Lynch
21No pass
Joel Greenblatt
2No pass
Charlie Munger
25No pass
Terry Smith
23No pass
Questions about Ascendis Pharma
Is Ascendis Pharma a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Ascendis Pharma AI analysis
What does Ascendis Pharma do?
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It is in Biotechnology, based in Hellerup, Denmark, with 1,189 employees.
Does Ascendis Pharma pay a dividend?
No. Ascendis Pharma does not pay a dividend at the moment; in 2025 it returned $17.4 million to shareholders by buying back its own shares.
Is Ascendis Pharma stock halal?
Yes. Ascendis Pharma passes our halal screen: its business is permitted and its debt is 5% of its market value, under the 30% limit. How we check
How has Ascendis Pharma stock done over the past year?
Up 33.4% over the past twelve months, to $275.39. It traded between $196.63 and $277.18, close to its high.
Who are Ascendis Pharma's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Ascendis Pharma's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.